Cortex Pharmaceuticals and the University of Alberta have agreed to collaborate on the development of Cortex's Ampakine technology to help prevent deaths from drug overdoses.
Subscribe to our email newsletter
University of Alberta professor Dr John Greer has demonstrated in both in vitro and in vivo animal models that selected Ampakine compounds can enhance respiratory drive and breathing rhythm at the level of the brainstem. Respiratory failure accounts for 25%-30% of drug-induced deaths, primarily caused by opiates and barbiturates.
Under the terms of the agreement, the University will receive an undisclosed upfront payment, milestones, and royalties, and Dr Greer will get multiple years of support to expand this research.